| |
| |
|
| Insider
Information: |
Ando Dale G |
| Relationship: |
VP, Therapeutic Dev. &... |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
107,328 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$56,240 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
107,328 |
|
|
| Total
Value |
$56,240 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Sangamo Biosciences Inc |
SGMO |
VP, Therapeutic Dev. &... |
2015-12-12 |
107,328 |
2011-12-08 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
80 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2011-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
76,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-01-28 |
4 |
AS |
$9.68 |
$145,158 |
D/D |
(15,000) |
88,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-01-28 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
103,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-07-26 |
4 |
AS |
$4.99 |
$25,320 |
D/D |
(5,000) |
73,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-07-27 |
4 |
AS |
$5.60 |
$84,000 |
D/D |
(15,000) |
73,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-07-27 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
88,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-08-27 |
4 |
AS |
$5.15 |
$25,903 |
D/D |
(5,000) |
68,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-09-05 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
83,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-09-05 |
4 |
AS |
$5.60 |
$84,000 |
D/D |
(15,000) |
68,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-10-15 |
4 |
AS |
$5.62 |
$28,283 |
D/D |
(5,000) |
63,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-10-26 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
78,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-10-26 |
4 |
AS |
$5.69 |
$113,935 |
D/D |
(20,000) |
58,534 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-11-26 |
4 |
AS |
$5.33 |
$25,232 |
D/D |
(4,736) |
55,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-11-27 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
70,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-11-27 |
4 |
AS |
$5.60 |
$84,000 |
D/D |
(15,000) |
55,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
90,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-12-26 |
4 |
AS |
$5.92 |
$100,718 |
D/D |
(17,000) |
88,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2012-12-26 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
103,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-01-28 |
4/A |
AS |
$9.68 |
$145,158 |
D/D |
(15,000) |
88,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-01-28 |
4/A |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
103,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-02-26 |
4 |
AS |
$8.64 |
$129,600 |
D/D |
(15,000) |
88,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-02-26 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
103,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-03-26 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
103,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-03-26 |
4 |
AS |
$9.18 |
$137,724 |
D/D |
(15,000) |
88,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-04-26 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
103,798 |
0 |
- |
|
80 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
